Retinitis Pigmentosa Clinical Trials 2024

Retinitis Pigmentosa Clinical Trials 2024

Retinitis Pigmentosa research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in retinitis pigmentosa clinical trials today.

Retinitis Pigmentosa Clinical Trials

Here are the 6 most popular medical studies for retinitis pigmentosa

Popular filter options for retinitis pigmentosa trials

RP Clinical Trials

View 34 RP medical studies.

Phase 3 Retinitis Pigmentosa Clinical Trials

View 34 phase 3 retinitis pigmentosa medical studies.

Retinitis Pigmentosa Clinical Trials With No Placebo

View 34 retinitis pigmentosa medical studies that do not have a placebo group.

View More Retinitis Pigmentosa Trials

See another 6 medical studies focused on retinitis pigmentosa.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to retinitis pigmentosa

What are the top hospitals conducting retinitis pigmentosa research?

When it comes to advancing the understanding and treatment of retinitis pigmentosa, several leading hospitals are making significant strides. In Dallas, the Retina Foundation of the Southwest is at the forefront with five ongoing clinical trials dedicated to this rare eye disorder. With a remarkable total of 20 completed trials since initiating their first study in 2004, this institution has been pivotal in shedding light on retinitis pigmentosa. Meanwhile, in Pittsburgh, the UPMC Eye Center is actively conducting three trials for this condition. Although relatively new in terms of its research endeavors, having started their first trial in 2017, they have already made valuable contributions towards unraveling the mysteries surrounding retinitis pigmentosa.

In Gainesville's Vitreo Retinal Associates center researchers too are focusing much on finding potential treatments for patients suffering from vision loss caused by retinitis pigmentosa where they run three active clinical examinations while keeping track of previously four held medical studies starting from only last year around2020.Universityof Michigan stands out as another formidable player by offering similar approach with holding three ongoing tests among which being no less than pioneers;it was back thereyears ago that itsfirst initiative began specifically addressingretinitispigmentosawhile DukeEyeCenter exhibits equally promising dedication by running additionalthreeactive investigations following footsteps throughfive previous experiments since stepping intothisjourney aimedat tacklingthe diseasefour years earlierin2015.

These esteemed institutions serve as beacons of hope for those affected by retinitis pigmentosa—a progressive and inherited degenerative eye disorder that often leads to severe visual impairment or blindness. Their collective efforts not only pave the way for potential breakthroughs but also underline the commitment and determination within the medical community to provide better care and quality of life for individuals grappling with this challenging condition worldwide.

Which are the best cities for retinitis pigmentosa clinical trials?

When it comes to retinitis pigmentosa clinical trials, several cities are leading the way in research and development. Ann Arbor, Michigan has 8 active trials that investigate treatments such as Genetic: AAV5-RPGR and N-acetylcysteine. Pittsburgh, Pennsylvania also plays a significant role with 7 ongoing studies focused on options like Step 1: SPVN06 dose 1 and Genetic: AAV5-RPGR. Additionally, Gainesville, Florida is actively conducting 7 trials exploring potential breakthroughs including BIIB111 and N-acetylcysteine. These cities offer individuals with retinitis pigmentosa access to cutting-edge clinical trials that bring hope for advancements in care and improved outcomes.

Which are the top treatments for retinitis pigmentosa being explored in clinical trials?

In the realm of retinitis pigmentosa, cutting-edge clinical trials are exploring a range of potential treatments. Notably, N-acetylcysteine has emerged as a promising option, currently being tested in one active trial dedicated to this condition. Another contender is OCU400 High Dose, which also boasts one ongoing trial focused on retinitis pigmentosa. Additionally, researchers are investigating the potential benefits of CNS10-NPC implantation and BS01 through their respective individual trials. As these innovative treatments gain momentum in clinical research since their first listings starting from 2020 onwards, there is hope for improved outcomes for individuals living with retinitis pigmentosa.

What are the most recent clinical trials for retinitis pigmentosa?

Exciting advancements in clinical trials for retinitis pigmentosa offer hope for those affected by this condition. One notable trial is focusing on SPVN06, which has progressed to Phase 2 after showing promising results in Phase 1. Additionally, the OCU400 High Dose trial has reached both Phase 1 and Phase 2 stages, demonstrating its potential as a treatment option. Another study explores Ultevursen's efficacy in treating retinitis pigmentosa, with positive outcomes observed during its progression from Phase 2 to Phase 3. Further research delves into CNS10-NPC implantation as a potential therapeutic intervention at the initial phase of investigation. Finally, MCO-010-High Dose shows promise based on encouraging findings during its advancement through Phase 2 trials. These recent clinical trials offer renewed optimism for individuals living with retinitis pigmentosa and highlight ongoing efforts to find effective treatments for this condition.

What retinitis pigmentosa clinical trials were recently completed?

Recently completed clinical trials have made significant strides in the field of retinitis pigmentosa, a degenerative eye disease. Notably, Aldeyra Therapeutics successfully concluded a trial for ADX-2191 in July 2022, offering hope for potential therapeutic options. Furthermore, jCyte's investigation into human retinal progenitor cells reached its completion milestone in December 2020. These advancements underscore the ongoing efforts to find effective treatments for retinitis pigmentosa and bring us closer to improving the lives of those affected by this condition.